Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, comments on the future role of chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of acute myeloid leukemia (AML). In particular, Dr Haubner highlights the need to improve manufacturing and manage toxicities. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.